This Glasgow Biotech Just Raised $46M to Tackle a Silent Kidney Threat

Jan de Vries · 2026-08-07

A small biotech company in Glasgow just secured a serious financial boost, and the implications could be huge for millions of people living with a common, yet often overlooked, genetic condition. Mironid, a biopharmaceutical firm, has closed a $46 million Series B financing round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through the next stages of clinical development. For those unfamiliar, ADPKD isn't just a niche medical issue. It's the most common hereditary kidney disorder in the world, affecting over 12 million people. The numbers are stark: about 50% of patients will develop kidney failure by the time they turn 60. That's a staggering statistic, and it's exactly why this new funding matters so much. ### Who's Backing the Bet? The round was led by the Scottish National Investment Bank, a clear signal of confidence in Mironid's approach. They weren't alone, though. The syndicate includes a who's who of existing backers, such as the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. When you see that level of institutional support, it's a pretty strong indicator that the science is on solid ground. Neil Wilkie, the CEO of Mironid, put it plainly: "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD." He emphasized that this financing will allow the company to progress the clinical development of their lead candidate, bringing them closer to transforming the treatment landscape for patients with rare kidney diseases. ### A New Approach to an Old Problem So, what makes Mironid different? The company was spun out of the University of Strathclyde and Heriot-Watt University in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. Their focus is on a first-in-class small molecule candidate that targets a cellular signal called cyclic AMP (cAMP). Here's the simplified version: In ADPKD patients, mutations in the PKD1 or PKD2 genes cause uncontrolled growth of fluid-filled cysts in the kidneys. Mironid's molecules are designed to directly target cAMP, a signal that's active across all stages of the disease, from initiation right through to end-stage. It drives both cell proliferation and fluid secretion within the cysts, so by tackling it head-on, the company aims to prevent new cyst formation and arrest the growth of existing ones. Preclinical data has shown significant efficacy and a favourable safety profile, including reductions in cyst number and kidney volume. The potential payoff? A more durable treatment option with an improved side-effect profile compared to existing therapies. ### Beyond the Lead Candidate The pipeline doesn't stop at ADPKD. Mironid is also targeting phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signalling pathways implicated in disease progression. They're also exploring applications in major inflammatory diseases and cancer. It's a research-and-development-led model, funded through venture capital and strategic investment, with the long-term goal of advancing programmes through preclinical and clinical trials toward commercialisation. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed up the broader significance: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." The fresh capital follows an earlier Series A extension round, bringing the company's total funding since inception to roughly $46.8 million. It's a solid war chest for a company that's clearly aiming high, and for the millions of patients waiting for better options, it's a genuinely encouraging development.